Technical Analysis for EPZM - Epizyme, Inc.

Grade Last Price % Change Price Change
grade F 10.03 0.55% 0.06
EPZM closed up 0.55 percent on Friday, October 11, 2019, on 1.42 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Nov 1

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical EPZM trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Multiple of Ten Bullish Other 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction 0.55%
Multiple of Ten Bearish Other 0.55%
Inside Day Range Contraction 0.55%
Oversold Stochastic Weakness 0.55%
Death Cross Bearish 2.66%

Older signals for EPZM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Epizyme, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, planning, and commercialization of various personalized therapeutics for the treatment of patients with genetically defined cancers. Its principal product candidates under development include EPZ-5676, an intravenously administered small molecule inhibitor of DOT1L that is in Phase I clinical trials for the treatment of mixed lineage rearranged leukemia (MLL-r); and EPZ-6438, an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients caused by an oncogenic point mutation in EZH2. The company has strategic collaboration and license agreements with Celgene Corporation and Celgene International Sàrl, as well as Glaxo Group Limited to discover, develop, and commercialize small molecule HMT inhibitors; and Eisai Co., Ltd. (Eisai) to license its EZH2 program. It also has a companion diagnostic collaboration with Abbott Molecular Inc. for the development of a companion diagnostic to identify patients with the MLL-r genetic alteration targeted by EPZ-5676; and with Roche Molecular Systems, Inc., as well as with Eisai for the development and commercialization of a companion diagnostic for use with EPZ-6438 product candidate. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Biotechnology Life Sciences Cancers Leukemia Celgene Non Hodgkin Lymphoma Eisai Ezh2 Treatment Of Non Hodgkin Lymphoma
Is EPZM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 16.59
52 Week Low 5.14
Average Volume 624,826
200-Day Moving Average 12.0482
50-Day Moving Average 11.8722
20-Day Moving Average 10.666
10-Day Moving Average 10.2485
Average True Range 0.6014
ADX 29.0
+DI 13.6838
-DI 24.5347
Chandelier Exit (Long, 3 ATRs ) 11.2958
Chandelier Exit (Short, 3 ATRs ) 11.539199999999999
Upper Bollinger Band 11.9687
Lower Bollinger Band 9.3633
Percent B (%b) 0.26
BandWidth 24.427152
MACD Line -0.593
MACD Signal Line -0.5902
MACD Histogram -0.0028
Fundamentals Value
Market Cap 586.41 Million
Num Shares 58.5 Million
EPS -2.07
Price-to-Earnings (P/E) Ratio -4.85
Price-to-Sales 55.00
Price-to-Book 6.25
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.53
Resistance 3 (R3) 10.56 10.44 10.44
Resistance 2 (R2) 10.44 10.31 10.42 10.41
Resistance 1 (R1) 10.23 10.23 10.17 10.20 10.39
Pivot Point 10.11 10.11 10.08 10.09 10.11
Support 1 (S1) 9.90 9.98 9.84 9.87 9.67
Support 2 (S2) 9.78 9.90 9.76 9.65
Support 3 (S3) 9.57 9.78 9.62
Support 4 (S4) 9.54